Cannabinoid system and neuroinflammation: Therapeutic perspectives in multiple sclerosis;El sistema cannabinoide en situaciones de neuroinflamación: Perspectivas terapéuticas en la esclerosis múltiple

Revista de Neurologia

Volumn 43, Issue 9, 2006, Pages 541-548

  Mestre, L ^a   Correa, F ^a   Docagne, F ^a   Clemente, D ^a   Ortega Gutierrez S ^c   Arevalo Martin A ^b   Molina Holgado, E ^b   Borrell A, J ^a   Guaza, Carmen ^a  

^a INSTITUTO CAJAL   (Spain)

^b HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Cannabinoids; Glial cells; Immune function; Multiple sclerosis; Neuroinflammation

Indexed keywords

CANNABINOID RECEPTOR; CYTOKINE;

ASTROCYTE; INFLAMMATION; MICROGLIA; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PROTEIN EXPRESSION; REMYELINIZATION; REVIEW; ANIMAL; GLIA; HUMAN; IMMUNOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROGLIA; RECEPTORS, CANNABINOID;

EID: 34347379750     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4309.2006259     Document Type: Review

References (54)

1. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646-7.
2. Lambert MD, Fowler CJ. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 2005; 48: 5059-87.
3. Offértaler L, Mo F, Bátkai S, Liu J, Begg M, Razdan RK, et al. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 2003; 63: 699-705.
4. Di Marzo V, Breivogel CS, Tao Q, Bridgen DT, Razdan RK, Zimmer AM, et al. Levels, metabolism and pharmacological activity of anandamide in CB1, cannabinoid receptor knock-out mice: evidence for non CB1, nor CB2 receptor mediated actions of anandamide in mouse brain. J Neurochem 2000; 75: 2434-44.
5. Di Marzo V, Blumberg PM, Szallasi A. Endovanilloid signalling in pain. Curr Opin Neurobiol 2002; 12: 372-9.
6. Matsuda LA, Lolait SJ, Browstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
7. Fernández-Ruiz J, Gómez M, Hernández M, De Miguel R, Ramos JA. Cannabinoids and gene expression during brain development. Neurotox Res 2004; 6: 389-91.
8. Molina-Holgado E, Arévalo-Martín A, Vela JM, Almazán G, Molina-Holgado F, Borrell J, et al. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signalling J Neurosci 2002; 22: 9742-53.
9. Aguado T, Monory K, Palazuelos J, Stella N, Cravat B, Lutz B, et al. The endocannabinoid system drives neural progenitors proliferation. FASEB J 2005; 19: 1704-6.
10. Aguado T, Palazuelos J, Monory K, Stella N, Cravat B, Lutz B, et al. The endocannabinoid system promotes astroglial differentiation by acting on neural progenitors cells. J Neurosci 2006; 26: 1551-61.
11. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232: 54-61.
12. Benito C, Núñez E, Tolón RM, Carrier EJ, Rábano A, Hillard CJ, et al. Cannabinoid CB2 receptors and fatty cid amide hydrolase are selectively overexpressed in neuritis plaques-associated glia in Alzheimer disease. J Neurosci 2003; 23: 11136-41.
13. Stella N. Cannabinoid signalling in glial cells. Glia 2004; 48: 267-77.
14. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie M, et al. Identification and functional characterization of brain-stem cannabinoid CB2 receptors. Science 2005; 310: 329-32.
15. Howlett AC. Pharmacology of cannabinoid receptors. Ann Rev Pharmacol Toxicol 1995; 273: 734-43.
16. Hájos N, Ledent C, Freund TF. Novel cannabinoid-sensitive receptors mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 2001; 106: 1-4.
17. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9.
18. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994; 372: 689-91.
19. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
20. Milman G, Maor Y, Abu-Lafi, S, Horowitz, M, Gallily R, Batkai, S, et al. N arachidonoyl-L-serine, an endocannabinoid like brain constituent with vasodilatory properties. Proc Natl Aca Sci USA 2006; 103: 2428-33.
21. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996; 384: 83-7.
22. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004; 141: 765-74.
23. 2 ethanolamide. J Pharmacol Exp Ther 2002; 301: 900-7.
24. Giufrida A, Parsone LH, Kerr TM, Rodríguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signalling in dorsal striatum. Nat Neurosci 1999; 2: 358-63.
25. Shliker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001; 22: 565-72.
26. Carlisle SJ, Marciano-Cabral F, Staab A, Ludwick C, Cabral GA. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol 2002; 2: 69-82.
27. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos K, et al. Non-psychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci 2003; 23: 1398-405.
28. Carrier EJ, Kearn CS, Barkmaier AJ, Breese NM, Yang W, Nithipatikom K, et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachydonyl glycerol, which increases proliferation via a CB2 receptor dependent mechanism. Mol Pharmacol 2004; 60: 155-63.
29. Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, De Ceballos M. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005; 25: 1904-13.
30. Waksman Y, Olson JM, Carlisle SJ, Cabral GA. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther 1999; 288: 1357-66.
31. Walter L, Franklin A, Witting A, Möller T, Stella N. Astrocytes in culture produce anandamide and other acylethanolamines. J Biol Chem 2002; 277: 20869-76.
32. Molina-Holgado F, Lledó A. Guaza C. Anandamide suppresses nitric oxide and TNF-α responses to Theiler's virus or endotoxin in astrocytes. NeuroReport 1997; 8: 1929-33.
33. Molina-Holgado F, Molina-Holgado E, Guaza C. The endogenous cannabinoid anandamide potentiates IL-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett 1998; 433: 139-42.
34. Molina-Holgado F, Molina-Holgado E, Guaza C, Rothwell NJ. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide induced nitric oxide release in astrocyte cultures. J Neurosci Res 2002; 67: 829-36.
35. Ortega-Gutiérrez S, Molina-Holgado E, Guaza C. Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. Glia 2005; 52: 166-8.
36. Molina-Holgado F, Pinteaux E, Moore J, Molina-Holgado E, Guaza C, Gibson RM, et al. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glial cells. J Neurosci 2003; 23: 6470-4.
37. Correa F, Mestre L, Docagne F, Guaza C. Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 synthesis in murine macrophages: role of IL-10 and ERK1/2 kinase signalling. Br J Pharmacol 2005; 145: 441-50.
38. Mestre L, Correa F, Arévalo-Martín A, Molina-Holgado E, Valenti M, Ortar G, et al. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis J Neurochem 2005; 92: 1327-39.
39. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al, UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placeb-control trial. Lancet 2003; 362: 1517-26.
40. Zajicek J, Sansers HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, et al. Cannabinoids in Multiple Sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005; 76: 1664-9.
41. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404: 84-7.
42. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2000; 15: 300-5.
43. Arévalo-Martín A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 2003; 23: 2511-6.
44. Croxford JL, Miller SD. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R (+) WIN55,212. J Clin Invest 2003; 111: 1231-40.
45. Ortega-Gutiérrez S, Molina-Holgado E, Arévalo-Martín A, Viso A, López-Rodríguez ML, Guaza C. Endocannabinoids uptake inhibition as therapeutic approach in a murine model of multiple sclerosis. FASEB J 2005; 19: 1338-44.
46. Cabranes A, Venderova K, De Lago E, Fezza F, Sánchez A, Mestre L, et al. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis Neurobiol Dis 2005; 20: 207-17.
47. Berrendero F, Sánchez A, Cabranes A, Puerta C, Ramos JA, García-Merino A, et al. Changes in cannabinoid CB1 receptors in striatal and cortical regions of rat with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 2001; 41: 195-202.
48. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, et al. The endogenous anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006; 49: 67-79.
49. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
50. Pryce G, Ahmed Z, Hankey DJR, Jackson SJ, Croxford JL, Pocok JM, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003; 126: 2191-202.
51. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, et al. Cannabinoids and neuroprotection in focal and global cerebral ischemia and neuronal cultures. J Neurosci 1999; 19: 2987-95.
52. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 2000; 97: 9561-6.
53. Klein TW. Cannabinoid based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005; 5: 400-11.
54. Ni X, Geller EB, Eppihimer MJ, Eisenstein TK, Adler MW, Tuma RF. Win 55212,2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in a experimental autoimmune encephalomyelitis model. Mult Scler 2004; 10: 258-64.